This company listing is no longer active
GENE Stock Overview
A molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Genetic Technologies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.77 |
| 52 Week High | AU$3.59 |
| 52 Week Low | AU$0.67 |
| Beta | 0.46 |
| 1 Month Change | 0% |
| 3 Month Change | -6.14% |
| 1 Year Change | -70.02% |
| 3 Year Change | -93.05% |
| 5 Year Change | -91.72% |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Genetic acquires AffinityDNA to bolster direct-to-consumer business
Jul 14Infinity Biologix launches Genetic Technologies' COVID-19 test
Jun 09Genetic Technologies launches COVID-19 risk test through partnership with Infinity Biologix
Jun 01Genetic Technologies’ COVID-19 risk test to be commercially available in U.S.
Apr 26Genetic Technologies appoints new CEO; Shares are up 8%
Jan 04Shareholder Returns
| GENE | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 2.1% | 0.7% |
| 1Y | -70.0% | -19.1% | 8.1% |
Return vs Industry: GENE underperformed the US Life Sciences industry which returned -3.7% over the past year.
Return vs Market: GENE underperformed the US Market which returned 26.1% over the past year.
Price Volatility
| GENE volatility | |
|---|---|
| GENE Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 9.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: GENE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine GENE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 55 | Kevin Camilleri | genetype.com |
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Genetic Technologies Limited Fundamentals Summary
| GENE fundamental statistics | |
|---|---|
| Market cap | US$3.58m |
| Earnings (TTM) | -US$7.59m |
| Revenue (TTM) | US$6.11m |
0.6x
P/S Ratio-0.5x
P/E RatioIs GENE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENE income statement (TTM) | |
|---|---|
| Revenue | AU$9.67m |
| Cost of Revenue | AU$3.76m |
| Gross Profit | AU$5.91m |
| Other Expenses | AU$17.93m |
| Earnings | -AU$12.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.083 |
| Gross Margin | 61.12% |
| Net Profit Margin | -124.24% |
| Debt/Equity Ratio | 35.2% |
How did GENE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 08:50 |
| End of Day Share Price | 2024/10/16 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genetic Technologies Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Marc Kennis | APP Securities Pty Ltd. |
| Kevin DeGeeter | Ladenburg Thalmann & Company |
| Chris Kallos | MST Financial Services Pty Limited |